Abstract:HER2/neu peptide-based vaccines can eliminate human tumors overexpressing the human epidermal growth factor receptor 2 (HER2/neu), but the efficacy of this therapeutic strategy is suboptimal. Heat shock proteins (HSPs) are capable of eliciting efficient cytotoxic T lymphocyte (CTL) responses by cross-presentation. To evaluate whether immunization with a HSP65–HER2 fusion peptide could selectively eliminate HER2 + B16 melanoma cells in a xenograft tumor mouse model, a HSP65–HER2 fusion peptide was incubated with immature dendritic cells (iDCs) in vitro to determine whether loading of iDCs with HSP65–HER2 could induce the expression of the immunomodulatory cell surface molecule, CD86. In vivo mouse immunizations with HSP65–HER2 or PBS (control) were performed to determine the antitumor effects by longitudinally monitoring changes in tumor volume, weight, and incidence. The effects on percentages of HER2 + B16 cells in tumors were assessed by confocal microscopy and flow cytometry. The results indicated that loading of iDCs with HSP65–HER2 induced the expression of CD86 in vitro, suggesting that the hybrid antigen was able to stimulate an immune response. Immunization with HSP65–HER2 had no significant influence on tumor weight or volume but significantly reduced tumor incidence (62.5 % in mice injected with 25 μg of HSP65–HER2 vs. 100 % in PBS-injected controls; P < 0.05). Confocal microscopy and flow cytometry analyses revealed that HSP65–HER2 immunization significantly reduced the percentages of HER2 + B16 cells in xenografted tumors (1.86 % vs. 30.56 % in PBS-injected controls; P = 0.01). Our findings suggest that immunization with the HSP65–HER2 fusion peptide selectively eliminates HER2 + B16 melanoma cells in a xenograft tumor mouse model and may represent a novel and efficacious targeted therapy of HER2/neu + tumors.

A Cpg Oligodeoxynucleotide Potentiates the Anti-Tumor Effect of Hsp65-Her2 Fusion Protein Against Her2 Positive B16 Melanoma in Mice

Vaccination with A Dna Vaccine Based on Human Psca and Hsp70 Adjuvant Enhances the Antigen-Specific Cd8(+) T-Cell Response and Inhibits the Psca(+) Tumors Growth in Mice

The anti-tumor effect of breast cancer fusion protein vaccine HSP65-HER2 in combination with CpG684

Immunization with a HSP65–HER2 Fusion Peptide Selectively Eliminates HER2+ B16 Melanoma Cells in a Xenograft Tumor Mouse Model

Mf59 Formulated With Cpg Odn As A Potent Adjuvant Of Recombinant Hsp65-Muc1 For Inducing Anti-Muc1(+) Tumor Immunity In Mice

Delivery System of Cpg Oligodeoxynucleotides Through Eliciting an Effective T Cell Immune Response Against Melanoma in Mice

Antitumor Activity of Mhsp65-Ttl Enhanced by Administration of Low Dose Cyclophosphamide in Pancreatic Cancer-Bearing Mice

Enhancement of HSP-MUC1 Antitumor Activity by Type C CpG-ODN BW005

Antitumor therapeutic effect induced by intestine- carcinoma cells vaccine expressing membrane- bound heat shock protein 70

Modulatory Effects of Tumor-Derived Heat Shock Protein in DNA Vaccination Against Nasopharyngeal Carcinoma

Dddt_a_325790 3953..3963

Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65.

Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.

The therapeutic potency of HSP65-GTL in GL261 glioma-bearing mice.

Recent Advances in Heat Shock Protein-Based Cancer Vaccines

Enhancement of DNA vaccine efficacy by targeting the xenogeneic human chorionic gonadotropin, survivin and vascular endothelial growth factor receptor 2 combined tumor antigen to the major histocompatibility complex class II pathway.

CpG Oligodeoxynucleotide Developed For Activating Primate Immune Responses Promotes Anti-Tumoral Effect Combine With Neo-Antigen Based mRNA Cancer Vaccine

Vaccination with B16 tumor cell lysate plus recombinant Mycobacterium tuberculosis Hsp70 induces antimelanoma effect in mice.

Enhanced antitumor immunity of nanoliposome-encapsulated heat shock protein 70 peptide complex derived from dendritic tumor fusion cells

Cpg Oligodeoxynucleotide Developed To Activate Primate Immune Responses Promotes Antitumoral Effects In Combination With A Neoantigen-Based Mrna Cancer Vaccine

The Fusion Protein of Hsp65 with Tandem Repeats of Beta-Hcg Acting As A Potent Tumor Vaccine in Suppressing Hepatocarcinoma